1968 Equivalent of M.D., Shanghai Traditional Chinese Medicine, TCM College, China
1981 Postgraduate diploma and Master's degree, Shanghai TCM College
1990 Ph.D., State University of New York, Buffalo

Dr. Chen has over ten years post-doctoral experience in molecular immunology and was involved in pioneering work on Cytokine immunotherapy at the Roswell Park Cancer Institute. His current research includes a $1 million, three-year, NIH grant, "Biodegradable Hydrogel Mediated Anti-Cancer Immunotherapy." The study seeks to assess the impact of injecting a time-release interleukin formulation into human tumors grafted onto immunodeficient mice. Although the anti-tumor and anti-viral effects of interleukins are well-known, their use in systemic injections has been linked to severe side effects and, in some cases, death. Dr. Chen will evaluate whether or not the tumor injection mobilizes human lymphocytes implanted in the tumor to mount an immune response, thus bypassing the severe side effects derived from systemic administration. His study is the first to assess whether injecting a time-release interleukin formulation into a tumor leads to a more evenly-distributed and sustained immune response.

A second study, "Intratumoral delivery of 125-IUdR for treatment of oral cancers," will primarily address the development and assessment of hydrogel as a carrier system for the sustained release of IUdR (5-iodo-2'-deoxyuridine), while also investigating the efficacy of intra-tumorally delivered IUdR for treatment of oral cancer.

A third study, "Identification of Predictor genes for Response or Resistance of Laryngo-pharyngeal Cancer to Chemo-radiotherapy," will select the differentially expressed genes in laryngo-pharyngeal cancers that are either responsive or resistant to chemo-radiotherapy. These genes will be validated by RT-PCR and then be used as a guide so that chemo-radiotherapy can be applied only to its responders.

Biodegradable Hydrogel Mediated Anti-Cancer Immunotherapy- NIH

Zylstra, S., F.A. Chen, S.K. Ghosh, E.A. Repasky, U. Rao, H. Takita, and R.B. Bankert, Membrane-associated glycoprotein (gp 160) identified on human lung tumors by a monoclonal antibody. Cancer Research, 1986. 46(12 Pt 1): p. 6446-51.

Sugiyama, Y., F.A. Chen, H. Takita, and R.B. Bankert, Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody [see comments]. Cancer Research, 1988. 48(10): p. 2768-73.

Bankert, R.B., T. Umemoto, Y. Sugiyama, F.A. Chen, E. Repasky, and S. Yokota, Human lung tumors, patients' peripheral blood lymphocytes and tumor infiltrating lymphocytes propagated in scid mice. Current Topics in Microbiology & Immunology, 1989. 152: p. 201-10.

Chen, F.A., E.A. Repasky, H. Takita, B.S. Schepart, and R.B. Bankert, Cell surface glycoprotein associated with human lung tumors that is similar to but distinct from the epidermal growth factor receptor. Cancer Research, 1989. 49(13): p. 3642-9.

Chen, F.A., E.A. Repasky, and R.B. Bankert, Human lung tumor-associated antigen identified as an extracellular matrix adhesion molecule. Journal of Experimental Medicine, 1991. 173(5): p. 1111-9.

Chen, F.A., T. Alosco, B.A. Croy, K. Narumi, D.H. Percy, and R.B. Bankert, Clones of tumor cells derived from a single primary human lung tumor reveal different patterns of beta 1 integrin expression. Cell Adhesion & Communication, 1994. 2(4): p. 345-57.

Narumi, K., F.A. Chen, R.B. Bankert, and H. Takita, Generation of monoclonal antibodies that distinguish between mesotheliomas and other tumor of the lung. Nippon Geka Hokan - Archiv fur Japanische Chirurgie, 1994. 63(4): p. 129-38.

Chen, F.A., S.S. Williams, W.C. Fanslow, and R.B. Bankert, Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T cell costimulation via CD40/CD40 ligand. Journal of Immunology, 1995. 155(6): p. 2833-40.

Sakakibara, T., Y. Xu, H.L. Bumpers, F.A. Chen, R.B. Bankert, M.A. Arredondo, S.B. Edge, and E.A. Repasky, Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. The Cancer Journal from Scientific American, 1996. 2(5): p. 291-300.

Sakakibara, T., F.A. Chen, H. Kida, K. Kunieda, R.E. Cuenca, F.J. Martin, and R.B. Bankert, Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Research, 1996. 56(16): p. 3743-6.

Williams, S.S., F.A. Chen, H. Kida, S. Yokata, K. Miya, M. Kato, M.P. Barcos, H.Q. Wang, T. Alosco, T. Umemoto, B.A. Croy, E.A. Repasky, and R.B. Bankert, Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. Journal of Immunology, 1996. 156(5): p. 1908-15.

Iwanuma, Y., F.A. Chen, N.K. Egilmez, H. Takita, and R.B. Bankert, Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Research, 1997. 57(14): p. 2937-42.

Egilmez, N.K., Y.S. Jong, Y. Iwanuma, J.S. Jacob, C.A. Santos, F.A. Chen, E. Mathiowitz, and R.B. Bankert, Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunology, Immunotherapy, 1998. 46(1): p. 21-4.

Bankert, R.B., F.A. Chen, Y. Sugiyama, and N. Egilmez, Patient immune response to tumors monitored using SCID mouse models. [Review] Immunological Investigations, 2000. 29(2): p. 171-6.

Conway, T.F.J., M.S. Sabel, M. Sugano, J.G. Frelinger, N.K. Egilmez, F.A. Chen, and R.B. Bankert, Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. Journal of Immunological Methods, 2000. 233(1-2): p. 57-65.

Kuriakose, M.A., F.A. Chen, N.K. Egilmez, Y.S. Jong, E. Mathiowitz, M.D. DeLacure, W.L. Hicks, Jr., T.L. Loree, and R.B. Bankert, Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head & Neck, 2000. 22(1): p. 57-63.

Sabel, M.S., T.F. Conway, F.A. Chen, and R.B. Bankert, Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. Journal of Immunotherapy, 2000. 23(3): p. 362-8.

Sabel, M.S., M. Yamada, Y. Kawaguchi, F.A. Chen, H. Takita, and R.B. Bankert, CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunology, Immunotherapy, 2000. 49(2): p. 101-8.

Sugano, M., N.K. Egilmez, S.J. Yokota, F.A. Chen, J. Harding, S.K. Huang, and R.B. Bankert, Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Research, 2000. 60(24): p. 6942-9.

Sugiyama, Y., M. Kato, F.A. Chen, S.S. Williams, Y. Kawaguchi, K. Miya, Y.S. Jong, E. Mathiowitz, N.K. Egilmez, and R.B. Bankert, Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. Journal of Immunotherapy, 2001. 24(1): p. 37-45.

Yamada, M., T. Shiroko, Y. Kawaguchi, Y. Sugiyama, N.K. Egilmez, F.A. Chen, and R.B. Bankert, CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors. International Journal of Cancer, 2001. 92(4): p. 589-99.

Egilmez, N.K., S.D. Hess, F.A. Chen, H. Takita T.F. Conway and R.B. Bankert, Human CD4+ effector T-cells mediate an indirect IL-12 and IFN? dependent suppression of autologous HLA-negative lung tumor xenografts in SCID mice. Cancer Research. 2002. 62:2611-17

Chen, F.A., M.A. Kuriakose, M.X. Zhou, M.D. DeLacure and R.L. Dunn. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model. Head & Neck. 2003. 25:554-60

Sok, J, M.A. Kuriakose, V.B. Mahajan, A.L. Pearlman, M.D. DeLacure, and F.A. Chen. Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. Arch Otolaryngol Head Neck Surg. 2003. 129:760-7024.

P. Zhang P, W.T. Chen, Q. Xu, F.A. Chen, M.A. Kuriakose, W.L. Qiu, Clustering and Prediction of the Gene Expression Profile of Oral and Maxillofacial Squamous Cell Carcinoma with or without Cisplatin Chemotherapy. China Journal of oral and maxillofacial surgery. Sept 2003. 1(3): 172-4

M.A. Kuriakose1, W.T. Chen2, Z.M. He1, A. Sikora1, P. Zhang2, F. Hsu3, M.D. Delacure1, Z.Y. Zhang2, F.A. Chen1. Selection and validation of differentially expressed genes in head and neck cancers. Cellular and Molecular Life Science. 2004. 61(11):1372-83

H.Y. Chuang, H, Liu, F.A. Chen, C.Y. Kao, and D.F. Hsu. Combination methods in microarray analysis. Proceedings of the 7th International Symposium on Parallel Architectures, Algorithms and Networks. 2004. IEEF Computer Society Press, Los Alamitos, USA. P 625-630